Merck has entered a partnership with global life science service Promega Corporation to co-develop technologies advancing drug screening and discovery.  The agreement will bring together Merck’s expertise in organoids and synthetic chemistry with Promega's assay and reporter technologies. The companies aim to develop assays capable of tracking cellular activity in real time using an innovative […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!